Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2024-09-24 Board/Management Inform…
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Dr. Ibrahim Hashmi as Vice President of Business Development at Voyageur Pharmaceuticals. It focuses on leadership changes and strategic business development initiatives. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no legal proceedings, and no report publication. The content is clearly about a management change announcement. Therefore, the document fits the category of Board/Management Information (MANG). The document length is sufficient and the content is detailed about the appointment, confirming it is not a brief notice but a full announcement. Confidence is high due to clear and explicit content about management appointment.
2024-09-24 English
Material change report - English.pdf
Regulatory Filings
2024-09-18 English
News release - English.pdf
Regulatory Filings
2024-09-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the introduction of five new barium contrast formulations by Voyageur Pharmaceuticals Ltd. It discusses product development, clinical testing phases, regulatory pathways (FDA 505(b)(2) drug pathway), and strategic business plans. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about new product development and business strategy rather than a financial report or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a report. It is also not a call transcript, management report, or any other specific financial or governance document. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2024-09-05 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings by the CFO of Voyageur Pharmaceuticals Ltd. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended May 31, 2024. The document is primarily an officer certification letter and does not contain actual financial data or substantive financial analysis. It references the interim filings but does not include them. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2965 characters), consistent with a certification letter rather than a full report.
2024-07-31 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended May 31, 2024. The text is primarily a certification letter and does not contain actual financial statements or substantive financial data. It explicitly states it is a certification under National Instrument 52-109 for venture issuers, which is a regulatory filing requirement. According to the Certification Rule, documents that are primarily officer certifications or attestations, even if referencing interim reports, should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3027 characters), and it is a certification, not the report itself. Therefore, the correct classification is Regulatory Filings (RNS).
2024-07-31 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.